أعرض تسجيلة المادة بشكل مبسط
| dc.creator |
Tamer İrfan Kaya |
|
| dc.date |
2011 |
|
| dc.date.accessioned |
2013-05-30T14:24:38Z |
|
| dc.date.available |
2013-05-30T14:24:38Z |
|
| dc.date.issued |
2013-05-30 |
|
| dc.identifier |
http://www.journalagent.com/z4/download_fulltext.asp?pdir=turkderm&plng=tur&un=TURKDERM-63497 |
|
| dc.identifier |
http://www.doaj.org/doaj?func=openurl&genre=article&issn=1019214X&date=2011&volume=45&issue=1&spage=44 |
|
| dc.identifier.uri |
http://koha.mediu.edu.my:8181/jspui/handle/123456789/6139 |
|
| dc.description |
Pemfigus is an autoimmune bullous skin disease, characterized by intraepidermal blisters. It is a severe and potentially life-threatening chronic disease with blisters and erosions on the mucosae and the skin. Treatment options do not differ for two most common types of pemphigus, pemphigus vulgaris and pemphigus foliaceus, except that the latter is usually less resistant to treatment and corticosteroids can often be started at lower doses. Systemic corticosteroids are still the most widely used drugs in the treatment of pemphigus and continue to be the mainstay of therapy for this disease. Adjuvant drugs are commonly used in combination with the aims of increasing efficacy and of having a steroid-sparing action, thereby allowing reduced corticosteroid side-effects. Mortality and complete remission rates have improved since the introduction of adjuvant drugs to pemphigus. Adjuvant drugs include immunoadsorbtion, corticosteroid pulse therapy, intravenous immunoglobulin (IVIG), immunosuppressive agents such as azathioprine, cyclophosphamide, mycophenolate mofetil and and anti-CD20 monoclonal antibody (rituximab). The lack of consensus in the published literature about the treatment of this disorder is responsible for different treatment strategies. Treatments need to be chosen after careful consideration of the potential benefits and side effects according to the patients’ medical condition. Here, both conventional therapies and novel treatment regimens for pemphigus are discussed. (Turkderm 2011; 45 Suppl 1: 44-53) |
|
| dc.publisher |
Galenos Yayincilik |
|
| dc.source |
Turkderm |
|
| dc.subject |
Intraepidermal autoimmune bullous diseases |
|
| dc.subject |
pemphigus vulgaris |
|
| dc.subject |
pemhigus foliaceus |
|
| dc.subject |
treatment |
|
| dc.title |
Treatment of Intraepidermal Autoimmune Bullous Diseases Sürekli Eğitim |
|
الملفات في هذه المادة
|
لا توجد أي ملفات مرتبطة بهذه المادة.
|
هذه المادة تبدو في المجموعات التالية:
أعرض تسجيلة المادة بشكل مبسط